Literature DB >> 29367229

PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.

Xu Han1, Marvin T Nieman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29367229      PMCID： PMC5788293          DOI： 10.1161/ATVBAHA.117.310550

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  16 in total

1.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

3.  Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.

Authors:  Nevin C Baker; Michael J Lipinski; Thibault Lhermusier; Ron Waksman
Journal:  Circulation       Date:  2014-10-07       Impact factor: 29.690

4.  YD-3, a novel inhibitor of protease-induced platelet activation.

Authors:  C C Wu; S W Huang; T L Hwang; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

5.  Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.

Authors:  S L French; J F Arthur; H Lee; W S Nesbitt; R K Andrews; E E Gardiner; J R Hamilton
Journal:  J Thromb Haemost       Date:  2016-06-22       Impact factor: 5.824

Review 6.  New developments in anticoagulants: Past, present and future.

Authors:  Jeffrey I Weitz; Job Harenberg
Journal:  Thromb Haemost       Date:  2017-06-08       Impact factor: 5.249

7.  Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Authors:  Benjamin M Scirica; Marc P Bonaca; Eugene Braunwald; Gaetano M De Ferrari; Daniel Isaza; Basil S Lewis; Felix Mehrhof; Piera A Merlini; Sabina A Murphy; Marc S Sabatine; Michal Tendera; Frans Van de Werf; Robert Wilcox; David A Morrow
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

8.  Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site.

Authors:  Marvin T Nieman; Alvin H Schmaier
Journal:  Biochemistry       Date:  2007-06-27       Impact factor: 3.162

9.  Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.

Authors:  M M Mumaw; M de la Fuente; D N Noble; M T Nieman
Journal:  J Thromb Haemost       Date:  2014-06-27       Impact factor: 5.824

Review 10.  Differential signaling by protease-activated receptors: implications for therapeutic targeting.

Authors:  Tejminder S Sidhu; Shauna L French; Justin R Hamilton
Journal:  Int J Mol Sci       Date:  2014-04-11       Impact factor: 5.923
View more
  9 in total

1.  Protease Activity in Vascular Disease.

Authors:  Megan A Slack; Scott M Gordon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-25       Impact factor: 8.311

Review 2.  The domino effect triggered by the tethered ligand of the protease activated receptors.

Authors:  Xu Han; Marvin T Nieman
Journal:  Thromb Res       Date:  2020-08-04       Impact factor: 3.944

3.  Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart.

Authors:  Anke C Fender; Sonja Kleeschulte; Svenja Stolte; Katja Leineweber; Markus Kamler; Johannes Bode; Na Li; Dobromir Dobrev
Journal:  Basic Res Cardiol       Date:  2020-01-07       Impact factor: 17.165

Review 4.  Platelet Signaling Pathways and New Inhibitors.

Authors:  Steven P Grover; Wolfgang Bergmeier; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04       Impact factor: 8.311

5.  Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.

Authors:  Robert H Lee; Tomohiro Kawano; Steven P Grover; Vanthana Bharathi; David Martinez; Dale O Cowley; Nigel Mackman; Wolfgang Bergmeier; Silvio Antoniak
Journal:  J Thromb Haemost       Date:  2021-11-10       Impact factor: 5.824

6.  Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19.

Authors:  Carolin Langnau; Anne-Katrin Rohlfing; Sarah Gekeler; Manina Günter; Simone Pöschel; Álvaro Petersen-Uribe; Philippa Jaeger; Alban Avdiu; Tobias Harm; Klaus-Peter Kreisselmeier; Tatsiana Castor; Tamam Bakchoul; Dominik Rath; Meinrad Paul Gawaz; Stella E Autenrieth; Karin Anne Lydia Mueller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-04-29       Impact factor: 8.311

7.  PAR4 activation involves extracellular loop 3 and transmembrane residue Thr153.

Authors:  Xu Han; Lukas Hofmann; Maria de la Fuente; Nathan Alexander; Krzysztof Palczewski; Marvin T Nieman
Journal:  Blood       Date:  2020-11-05       Impact factor: 25.476

Review 8.  Mechanisms Underlying Dichotomous Procoagulant COAT Platelet Generation-A Conceptual Review Summarizing Current Knowledge.

Authors:  Lucas Veuthey; Alessandro Aliotta; Debora Bertaggia Calderara; Cindy Pereira Portela; Lorenzo Alberio
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

Review 9.  The Roles of GRKs in Hemostasis and Thrombosis.

Authors:  Xi Chen; Xuefei Zhao; Matthew Cooper; Peisong Ma
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.